Anthem Biosciences Ltd Technical Momentum Shifts Amid Sideways Trend

Technical Trend Overview and Price Movement

As of 7 April 2026, Anthem Biosciences Ltd closed at ₹658.90, down slightly by 0.35% from the previous close of ₹661.20. The stock’s intraday range was relatively narrow, with a low of ₹654.30 and a high of ₹668.05, indicating limited volatility. Over the past 52 weeks, the share price has fluctuated between ₹579.45 and ₹873.25, highlighting a significant range of movement within the mid-cap Pharmaceuticals & Biotechnology space.

The technical trend has shifted from mildly bullish to sideways, signalling a pause in upward momentum. This change suggests that the stock is currently consolidating, with neither buyers nor sellers exerting dominant control. Such sideways movement often precedes a decisive breakout or breakdown, making it a critical phase for technical traders and investors alike.

MACD and Momentum Indicators

The Moving Average Convergence Divergence (MACD) indicator on the weekly chart remains mildly bullish, indicating that the short-term momentum still favours buyers, albeit with reduced conviction. However, the monthly MACD does not provide a clear directional signal, reflecting uncertainty in the longer-term trend. This divergence between weekly and monthly MACD readings suggests that while short-term momentum has not completely dissipated, the broader trend lacks strength.

The absence of a strong monthly MACD signal aligns with the sideways trend observed in other technical parameters, implying that investors should exercise caution and monitor for confirmation before committing to new positions.

RSI and Overbought/Oversold Conditions

The Relative Strength Index (RSI) on both weekly and monthly timeframes currently shows no definitive signal. This neutral RSI reading indicates that the stock is neither overbought nor oversold, reinforcing the sideways price action. The lack of RSI extremes suggests that the stock is in equilibrium, with balanced buying and selling pressures.

For investors, this means there is no immediate warning of a reversal due to overextension, but also no clear impetus for a strong directional move based on momentum exhaustion.

Moving Averages and Bollinger Bands

Daily moving averages have not provided a decisive trend signal recently, consistent with the sideways momentum. The Bollinger Bands on the weekly chart also reflect this consolidation, showing a narrowing band width that typically precedes a volatility expansion. On the monthly scale, Bollinger Bands similarly indicate a lack of directional bias, further confirming the current phase of price stability.

Investors should watch for a breakout above the upper Bollinger Band or a breakdown below the lower band as potential triggers for renewed momentum.

Volume and Dow Theory Signals

On-Balance Volume (OBV) readings on both weekly and monthly charts show no clear trend, indicating that volume is not currently confirming any price direction. Similarly, Dow Theory analysis reveals no established trend on either timeframe, reinforcing the sideways technical stance.

The lack of volume confirmation suggests that market participants are hesitant, possibly awaiting fresh catalysts or clearer signals before increasing exposure.

Comparative Performance Against Sensex

Examining Anthem Biosciences Ltd’s returns relative to the benchmark Sensex provides additional context. Over the past week, the stock has marginally outperformed the Sensex, delivering a 0.4% gain compared to the Sensex’s 3.0% rise. However, over the one-month period, Anthem declined by 0.33%, outperforming the Sensex’s sharper 6.1% fall. Year-to-date, the stock has gained 1.21%, significantly outperforming the Sensex’s 13.04% decline.

Longer-term data is not available for the stock, but the Sensex’s 3-year, 5-year, and 10-year returns stand at 23.86%, 50.62%, and 197.61% respectively, underscoring the broader market’s robust performance over extended periods.

These relative returns suggest that Anthem Biosciences Ltd has demonstrated resilience amid broader market weakness, though its recent sideways technical posture indicates a need for renewed momentum to sustain outperformance.

Mojo Score and Analyst Ratings

Anthem Biosciences Ltd currently holds a Mojo Score of 40.0, categorised as a Sell rating, a downgrade from its previous Hold grade as of 6 April 2026. This downgrade reflects a deterioration in the stock’s technical and fundamental outlook as assessed by MarketsMOJO’s proprietary scoring system.

The mid-cap classification of the company places it in a segment often characterised by higher volatility and sensitivity to sector-specific developments. The downgrade to Sell suggests that investors should exercise caution and consider the stock’s current sideways momentum and lack of strong technical confirmation before increasing exposure.

Outlook and Investor Considerations

In summary, Anthem Biosciences Ltd is currently navigating a technical transition from mild bullishness to a sideways consolidation phase. Key momentum indicators such as the weekly MACD remain mildly positive, but monthly signals and volume-based indicators lack conviction. The RSI’s neutral stance and the narrowing Bollinger Bands further reinforce the stock’s current equilibrium.

Investors should monitor for a breakout above the recent highs near ₹668 or a breakdown below the intraday lows around ₹654 to identify the next directional move. Given the recent downgrade to a Sell rating and the sideways technical posture, a cautious approach is warranted, with attention to broader sector trends and market catalysts.

Comparative performance against the Sensex indicates relative resilience, but the stock’s momentum must improve to sustain outperformance and justify a more bullish stance.

Conclusion

Anthem Biosciences Ltd’s current technical landscape suggests a period of consolidation with limited directional momentum. While short-term indicators hint at mild bullishness, the absence of strong volume confirmation and neutral RSI readings imply that the stock is in a holding pattern. Investors should await clearer signals before committing to new positions, keeping in mind the recent downgrade and the broader market context.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →